All the Active Ingredient Drugs
Aromatase Inhibitor. Anastrozole 1 mg. F.C. TAB: 30. Not recommend. in child.
Adults, includ. elderly: 1 tab 1 x dly.
Mild/mod. ren. impair: No dose
change. Mild hepat. impair: No dose
change.
Tmt. advanced breast cancer in
postmenopaus. women. Efficacy not
demonstrat. in estrogen recept. neg. pts
unless with prev. +ive. clin. response to
tamoxifen; adjuv. tmt. postmenopaus.
women with hormone recept. +ive early
invas. breast cancer; adjuv. tmt. early
breast cancer in hormone recept. +ive
postmenopaus. women who have
received 2-3 yrs adjuv. tamoxifen.
C/I: Pre-menopaus. women; pregn.,
lactat., severe renal impair. (creatin.
clearance < 20 ml/min.); mod.-severe
hepat. dis; known hypersens., co-admin
of estrogen-contain. ther./tamoxifen
ther.
Aromatase Inhibitor. Anastrozole 1 mg. TAB: 30. Not recommend. in child.
Adults, includ. elderly: 1 mg 1 x dly.
Mild/mod. ren. impair: No dose
change. Mild hepat. impair: No dose
change.
Tmt. advanced breast cancer in
postmenopaus. women. Efficacy not
demonstrat. in estrogen recept. neg. pts
unless with prev. pos. clin. response to
tamoxifen; adjuv. tmt. postmenopaus.
women with hormone recept. +ive early
invas. breast cancer; adjuv. tmt. early
breast cancer in hormone recept. +ive
postmenopaus. women who have
received 2-3 yrs adjuv. tamoxifen.
C/I: Pre-menopaus. women; pregn.,
lactat., severe renal impair. (creatin.
clearance < 20 ml/min.); mod.-severe
hepat. dis; known hypersens., co-admin
of estrogen-contain. ther./tamoxifen
ther.
Aromatase Inhibitor. Anastrozole 1 mg. TABS: 28. Adults and elderly: 1 tab. dly.
Advanced breast cancer in post-menopaus.
women. Adjuv. tmt of
postmenopaus. women with hormone
receptor-positive early invasive breast
cancer. Adjuv. tmt. early breast cancer in
hormone receptor +tive postmenopaus.
women who have received 2-3 yrs.
adjunct. tamoxifen.
C/I: Severe ren. impair., mod. or severe
hepat. dis., pregn., lact.